Foundation Medicine

Happy 4th of July! Wishing all of our US colleagues, patients and partners a wonderful and safe holiday.

Approval Announcement – proud to share that our blood-based, liquid biopsy test has been approved by the FDA as a companion diagnostic to help identify patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer who may be appropriate for a specific targeted therapy. This decision follows the approval of our tissue-based test for the same therapy in August 2023. Learn more: https://bit.ly/45OTClB

Meet Bianca, an Accessioning Supervisor who has excelled at Foundation Medicine, driven by her genuine love of helping others. A certified nursing assistant for 12 years, Bianca had plans of becoming a nurse until a life event prompted her to pivot into the lab — eventually landing at Foundation Medicine. She has made an immeasurable impact on coworkers and patients by leading with heart. Read our latest #careers #blog to learn about Bianca shares and the dedicated approach that has led to her personal growth and professional success: https://bit.ly/4czjiVC #WeAreFMI

Proud to support Living Beyond Breast Cancer on the launch of this campaign and to help increase education and understanding around #biomarker testing. Learn more in the post below.

Today we recognize Juneteenth. While strides have been made, there is still a lot of work to be done in the fight against racial and systemic injustices faced by Black Americans. Within our workplace, our communities and beyond, we can all contribute to fostering places of inclusivity, standing up for justice and speaking out against racism.

New #research aimed to inform optimal clinical considerations for comprehensive genomic profiling (CGP) using tissue- & blood-based biopsies in patients with HR-positive, HER2-negative metastatic breast cancer (MBC). Findings showed that CGP can help oncologists better understand why HR-positive, HER2-negative MBC patients show resistance to certain therapies and how to optimize first and subsequent lines of therapy due to acquired resistance mechanisms. Read more here: https://bit.ly/4bfAui4

Recognizing National Black Family Cancer Awareness Week. We remain dedicated to spreading knowledge and awareness around cancer within one of the most vulnerable segments of the US population. Through our connections and work in our communities, we are committed to helping enable greater access to precision medicine and to making cancer care more equitable. Click through below for some key facts and information. #BlackFamCan

Honored to have been a part of #ASCO24. Take a look back at our time in Chicago last week.

“High-quality companion diagnostics are critical to inform treatment decisions, and they are especially important for detecting complex biomarkers in patients without any therapeutic options. We’re proud to partner with Repare Therapeutics as they work to advance this potential first-in-class therapy for patients with high unmet need.” – Troy Schurr, Chief Biopharma Business Officer, Foundation Medicine Learn more about our new #collaboration with Repare Therapeutics: https://bit.ly/3VCE4xQ

Precision medicine and #biomarkers have created the opportunity for clinical trials to move faster and have increased chances of success, with studies showing that trials using biomarkers have two to six times the overall probability of success compared to trials without biomarkers. Join Foundation Medicine for an upcoming #webinar – “Incorporating Biomarkers in Early- and Late-Stage Clinical Trials” – to learn more. Register here: https://bit.ly/3VBQkPa